SPY295.44+0.56 0.19%
DIA244.88-0.14 -0.06%
IXIC9,324.59+39.71 0.43%

Credit Suisse Maintains Neutral on AnaptysBio, Raises Price Target to $16

Credit Suisse analyst Martin Auster maintains AnaptysBio (NASDAQ:ANAB) with a Neutral and raises the price target from $14 to $16.

Benzinga · 05/07/2020 13:42

Credit Suisse analyst Martin Auster maintains AnaptysBio (NASDAQ:ANAB) with a Neutral and raises the price target from $14 to $16.